Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013940 | 0.81 | MMP2 (0.48) | ALDH1A1MAPTSMN1; SMN2CA2MMP2 | |
| SCHEMBL23345377 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2CA2CA1 | |
| SCHEMBL15840367 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2CA2CA1 | |
| SCHEMBL634085 | 0.81 | ALDH1A1 (0.79) | ALDH1A1MAPTSMN1; SMN2CA2MMP2 | |
| SCHEMBL3411592 | 0.80 | KDM4E (0.55) | ALDH1A1CA2MMP2CA1MMP1 | |
| SCHEMBL14676363 | 0.80 | MMP2 (0.52) | ALDH1A1CA2MMP2CA1MMP1 | |
| SCHEMBL12169369 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTSMN1; SMN2CA2CA1 | |
| SCHEMBL2408403 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CA2MMP2 | |
| SCHEMBL1479992 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CA2CA1 | |
| SCHEMBL797959 | 0.79 | CA2 (0.55) | ALDH1A1MAPTCA2MMP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903015-A | Process for the preparation of N-fluoro-N-alkylsulfonamides | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | claimed |
| US-20260078111-A1 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| WO-2024124023-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-117903015-A | Process for the preparation of N-fluoro-N-alkylsulfonamides | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-116891463-A | Heterocyclic compounds as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-10-05 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1012142-B1 | 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6046217-A | TREATING AN INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMPRISING ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A NONTOXIC 3-PHENYL SUBSTITUTED PYRIDINES | MERCK FROSST CANADA & CO. (CA) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | ALDH1A1 2304/4885MAPT 772/4885SMN1; SMN2 2289/4885 |
| US-20230312616-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3972/4885MAPT 4877/4885SMN1; SMN2 4797/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | ALDH1A1 424/4885MAPT 4616/4885SMN1; SMN2 4010/4885 |
| US-20260078111-A1 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | CA6, CA9, CA7 | ALDH1A1 88/4885MAPT 4666/4885SMN1; SMN2 2436/4885 |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3972/4885MAPT 4877/4885SMN1; SMN2 4797/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | ALDH1A1 2021/4885MAPT 2434/4885SMN1; SMN2 1580/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | ALDH1A1 2021/4885MAPT 2434/4885SMN1; SMN2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.